Machine Learning Unveils Key Redox Signatures for Enhanced Breast Cancer Therapy

Overview

Journal Cancer Cell Int

Publisher Biomed Central

Date 2024 Nov 10

PMID 39522039

Authors

Tao Wang

Shu Wang

Zhuolin Li

Jie Xie

Kuiying Du

Jing Hou

Affiliations

Soon will be listed here.

Abstract

Background: Breast cancer remains a leading cause of mortality among women worldwide, necessitating innovative prognostic models to enhance treatment strategies.

Methods: Our study retrospectively enrolled 9,439 breast cancer patients from 12 independent datasets and single-cell data from 12 patients (64,308 cells). Moverover, 30 in-house clinical cohort were collected for validation. We employed a comprehensive approach by combining ten distinct machine learning algorithms across 108 different combinations to scrutinize 88 pre-existing signatures of breast cancer. To affirm the efficacy of our developed model, immunohistochemistry assays were performed. Additionally, we investigated various potential immunotherapeutic and chemotherapeutic interventions.

Results: This study introduces an Artificial Intelligence-aided Redox Signature (AIARS) as a novel prognostic tool, leveraging machine learning to identify critical redox-related gene signatures in breast cancer. Our results demonstrate that AIARS significantly outperforms existing prognostic models in predicting breast cancer outcomes, offering a robust tool for personalized treatment planning. Validation through immunohistochemistry assays on samples from 30 patients corroborated our results, underscoring the model's applicability on a wider scale. Furthermore, the analysis revealed that patients with low AIARS expression levels are more responsive to immunotherapy. Conversely, those exhibiting high AIARS were found to be more susceptible to certain chemotherapeutic agents, including vincristine.

Conclusions: Our study underscores the importance of redox biology in breast cancer prognosis and introduces a powerful machine learning-based tool, the AIARS, for personalized treatment strategies. By providing a more nuanced understanding of the redox landscape in breast cancer, the AIARS paves the way for the development of redox-targeted therapies, promising to enhance patient outcomes significantly. Future work will focus on clinical validation and exploring the mechanistic roles of identified genes in cancer biology.

References

Mariathasan S, Turley S, Nickles D, Castiglioni A, Yuen K, Wang Y . TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018; 554(7693):544-548. PMC: 6028240. DOI: 10.1038/nature25501. View

Jorgenson T, Zhong W, Oberley T . Redox imbalance and biochemical changes in cancer. Cancer Res. 2013; 73(20):6118-23. PMC: 3800221. DOI: 10.1158/0008-5472.CAN-13-1117. View

Gorrini C, Harris I, Mak T . Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov. 2013; 12(12):931-47. DOI: 10.1038/nrd4002. View

Li T, Fan J, Wang B, Traugh N, Chen Q, Liu J . TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer Res. 2017; 77(21):e108-e110. PMC: 6042652. DOI: 10.1158/0008-5472.CAN-17-0307. View

Browaeys R, Saelens W, Saeys Y . NicheNet: modeling intercellular communication by linking ligands to target genes. Nat Methods. 2019; 17(2):159-162. DOI: 10.1038/s41592-019-0667-5. View

Finotello F, Mayer C, Plattner C, Laschober G, Rieder D, Hackl H . Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data. Genome Med. 2019; 11(1):34. PMC: 6534875. DOI: 10.1186/s13073-019-0638-6. View

Newman A, Liu C, Green M, Gentles A, Feng W, Xu Y . Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015; 12(5):453-7. PMC: 4739640. DOI: 10.1038/nmeth.3337. View

Hugo W, Zaretsky J, Sun L, Song C, Moreno B, Hu-Lieskovan S . Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell. 2016; 165(1):35-44. PMC: 4808437. DOI: 10.1016/j.cell.2016.02.065. View

Wang L, Liu Z, Liang R, Wang W, Zhu R, Li J . Comprehensive machine-learning survival framework develops a consensus model in large-scale multicenter cohorts for pancreatic cancer. Elife. 2022; 11. PMC: 9596158. DOI: 10.7554/eLife.80150. View

10.

Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X . Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018; 24(10):1550-1558. PMC: 6487502. DOI: 10.1038/s41591-018-0136-1. View

11.

Zeng D, Ye Z, Shen R, Yu G, Wu J, Xiong Y . IOBR: Multi-Omics Immuno-Oncology Biological Research to Decode Tumor Microenvironment and Signatures. Front Immunol. 2021; 12:687975. PMC: 8283787. DOI: 10.3389/fimmu.2021.687975. View

12.

Becht E, Giraldo N, Lacroix L, Buttard B, Elarouci N, Petitprez F . Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 2016; 17(1):218. PMC: 5073889. DOI: 10.1186/s13059-016-1070-5. View

13.

McGinnis C, Murrow L, Gartner Z . DoubletFinder: Doublet Detection in Single-Cell RNA Sequencing Data Using Artificial Nearest Neighbors. Cell Syst. 2019; 8(4):329-337.e4. PMC: 6853612. DOI: 10.1016/j.cels.2019.03.003. View

14.

Wang D, Liu B, Zhang Z . Accelerating the understanding of cancer biology through the lens of genomics. Cell. 2023; 186(8):1755-1771. DOI: 10.1016/j.cell.2023.02.015. View

15.

Meyers R, Bryan J, McFarland J, Weir B, Sizemore A, Xu H . Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells. Nat Genet. 2017; 49(12):1779-1784. PMC: 5709193. DOI: 10.1038/ng.3984. View

16.

Yang C, Huang X, Li Y, Chen J, Lv Y, Dai S . Prognosis and personalized treatment prediction in TP53-mutant hepatocellular carcinoma: an in silico strategy towards precision oncology. Brief Bioinform. 2020; 22(3). DOI: 10.1093/bib/bbaa164. View

17.

Wang T, Li T, Li B, Zhao J, Li Z, Sun M . Immunogenomic Landscape in Breast Cancer Reveals Immunotherapeutically Relevant Gene Signatures. Front Immunol. 2022; 13:805184. PMC: 8829007. DOI: 10.3389/fimmu.2022.805184. View

18.

Cabili M, Trapnell C, Goff L, Koziol M, Tazon-Vega B, Regev A . Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses. Genes Dev. 2011; 25(18):1915-27. PMC: 3185964. DOI: 10.1101/gad.17446611. View

19.

Lennicke C, Cocheme H . Redox metabolism: ROS as specific molecular regulators of cell signaling and function. Mol Cell. 2021; 81(18):3691-3707. DOI: 10.1016/j.molcel.2021.08.018. View

20.

Racle J, Gfeller D . EPIC: A Tool to Estimate the Proportions of Different Cell Types from Bulk Gene Expression Data. Methods Mol Biol. 2020; 2120:233-248. DOI: 10.1007/978-1-0716-0327-7_17. View